Taysha Gene Therapies Issues Stock Grants to Four New Hires
Taysha granted RSUs and stock options to four new employees as hiring incentives under a Nasdaq-compliant inducement plan.
Taysha Gene Therapies, Inc. (Nasdaq: TSHA) disclosed Thursday that its Board of Directors' Compensation Committee approved equity awards for four newly hired employees on October 1, 2026, using a structured inducement plan allowed under Nasdaq rules.
The grants consist of restricted stock units representing 384,000 shares of Taysha common stock, along with an option to purchase an additional 92,400 shares. The awards were issued under the company's 2023 Inducement Plan, a vehicle specifically designed to offer equity compensation to incoming talent without requiring a shareholder vote, in compliance with Nasdaq Listing Rule 5635(c)(4).
Read more Biogen's Litifilimab Shows Durable CLE Results at 52 Weeks →
Dallas-based Taysha is a clinical-stage biotechnology firm concentrating on adeno-associated virus gene therapies targeting severe monogenic diseases of the central nervous system. Inducement grants of this type are a common tool in the biotech sector, where companies compete aggressively for specialized scientific and operational talent by offering equity tied directly to employment agreements.
The use of a dedicated inducement plan rather than the company's broader equity pool signals Taysha's intent to preserve existing shareholder dilution limits while still attracting key personnel as it advances its CNS therapy pipeline.
Continue reading at GlobeNewswire - Industry News on Financial Services
